The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the ...
The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket. On Tuesday, the agency sent warning ...